Uncategorized
mazdutide vs tirzepatide
Mazdutide vs Tirzepatide: Mechanism, Clinical Data, and Research Differences
Both mazdutide and tirzepatide belong to the same generation of dual-receptor agonist peptides, and both have generated significant interest in metabolic research. But despite sharing a GLP-1 component, they work through fundamentally different mechanisms — and that distinction matters enormously for researchers studying energy expenditure, adipose tissue biology, and glycaemic regulation.
This post breaks down exactly where they overlap, where they diverge, and what the current clinical evidence shows.
The Core Difference: GIP vs Glucagon
Both peptides activate the GLP-1 receptor — the shared foundation that drives satiety signalling, gastric emptying delay, and glucose-dependent insulin secretion. The divergence is in the second receptor each targets.
Tirzepatide is a dual GLP-1 / GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) potentiates insulin secretion and is thought to influence fat metabolism, particularly in adipose tissue. The combination is what gives tirzepatide its potent effect on both body weight and blood glucose.
Mazdutide is a dual GLP-1 / glucagon receptor agonist. The glucagon component adds a distinct mechanism tirzepatide does not directly offer: it stimulates the liver to mobilise stored energy and may increase resting energy expenditure through hepatic AMPK activation and fatty acid oxidation — effects that operate independently of insulin signalling.
| Tirzepatide | Mazdutide | |
|---|---|---|
| First receptor | GLP-1 | GLP-1 |
| Second receptor | GIP | Glucagon |
| Developer | Eli Lilly | Innovent Biologics |
| Approval status | FDA-approved (US, UK, EU) | Approved in China (June 2025) only |
| Brand names | Mounjaro, Zepbound | IBI362 |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
Clinical Data: Weight Reduction
No head-to-head trial between the two compounds has been published. All comparisons are drawn from separate trials conducted in different populations with different study designs — and should be interpreted accordingly.
Tirzepatide has the most robust dataset. In the SURMOUNT-1 phase 3 trial, participants receiving 15mg tirzepatide weekly achieved a mean body weight reduction of up to 20.9% over 72 weeks. Across the broader SURPASS programme for type 2 diabetes, the 5mg, 10mg, and 15mg doses consistently produced HbA1c reductions of 1.9–2.6% from baseline.
Mazdutide data comes primarily from trials in Chinese populations. In the GLORY-1 phase 3 trial published in the New England Journal of Medicine, mazdutide produced approximately 14% mean body weight reduction, with higher doses under investigation that may narrow the gap. A separate phase 1 high-dose trial published in August 2025 in Diabetes, Obesity and Metabolism showed promising results at escalated doses.
In trials conducted in China comparing the two directly at 48 weeks, tirzepatide achieved approximately 17.5% average weight loss versus mazdutide’s 14% — though again, these are not controlled head-to-head comparisons and population differences apply.
Mechanistic Implications for Research
The choice between the two compounds in a research context depends on what biological pathway you are studying.
Where tirzepatide has the edge:
- Incretin biology and dual-receptor insulin secretion models
- Adipose tissue remodelling via GIP receptor activity
- Well-characterised pharmacokinetics with extensive published data
- Available with FDA approval, meaning more accessible for research procurement
Where mazdutide has distinct research value:
- Hepatic lipid oxidation and fatty acid mobilisation via glucagon receptor activation
- Energy expenditure models independent of insulin signalling
- Research into glucagon receptor agonism in hepatic steatosis and NAFLD/NASH models
- Studying metabolic effects in populations with incretin resistance — the glucagon pathway bypasses GLP-1 receptor downregulation
Researchers comparing mazdutide and tirzepatide in hepatic steatosis models have noted greater reductions in intrahepatic triglyceride content with glucagon-inclusive peptides, attributed to direct lipid mobilisation rather than glucose-dependent insulin sensitisation.
Regulatory and Availability Status
This is where the compounds differ most practically for researchers outside China.
Tirzepatide is fully approved by the FDA (2022 for T2D as Mounjaro, 2023 for obesity as Zepbound), the UK’s MHRA, and the EMA. Compounded research-grade tirzepatide is widely available from peptide suppliers for laboratory use.
Mazdutide received its first regulatory approval in China in June 2025 for weight management, followed by a second approval in September 2025 for type 2 diabetes. It has not received FDA, MHRA, or EMA approval and is not currently available in the US or UK outside of trial settings. International trials are underway with a view to global approval, but no timeline has been confirmed.
Where Mazdutide Sits in the Broader Landscape
It is worth contextualising mazdutide within the wider next-generation metabolic peptide pipeline. Triple agonist compounds like retatrutide (GIP/GLP-1/glucagon) are also advancing through trials, with Eli Lilly’s phase 2 data showing mean weight reductions of 24.2% at 48 weeks at the 12mg dose — exceeding both tirzepatide 15mg and mazdutide in separate comparisons.
For researchers interested in this broader class, our post on What Are Peptides? A Researcher’s Introduction provides the mechanistic groundwork, and our tirzepatide reconstitution and dosing guide covers the practical research setup for tirzepatide specifically.
For a broader overview of the evolving GLP-1 receptor agonist class, the SURPASS clinical trial programme on ClinicalTrials.gov and the GLORY-1 trial data via NEJM provide the primary source literature.
Summary
| Factor | Tirzepatide | Mazdutide |
|---|---|---|
| Mechanism | GLP-1 + GIP | GLP-1 + Glucagon |
| Weight loss (separate trials) | Up to 20.9% (72 wks) | ~14% (48 wks) |
| HbA1c reduction | 1.9–2.6% | Comparable |
| Energy expenditure effect | Indirect (via GIP/adipose) | Direct (via hepatic glucagon) |
| Regulatory status | FDA / MHRA / EMA approved | China only (2025) |
| Research data depth | Extensive (phase 3 global) | Growing (primarily China) |
| Research procurement | Widely available | Limited outside China |
Both compounds represent meaningful advances in dual-agonist peptide pharmacology. Tirzepatide currently holds the advantage of regulatory approval, global clinical data, and research accessibility. Mazdutide offers a mechanistically distinct glucagon pathway that may prove valuable in hepatic, energy expenditure, and incretin-resistance research models — particularly as higher dose data matures.
All content is provided for educational and research purposes only. Peptides available at Penguin Peptide Lab are supplied strictly for laboratory research use. Nothing in this post constitutes medical advice. Browse our research catalogue at penguinpeptideco.com/shop.
